undamentalytics Newsletter
Sign in

Biocryst Pharmaceuticals Inc balance sheet

At the end of fiscal 2025, Biocryst Pharmaceuticals Inc had total assets of $514m, total liabilities of $633m and shareholders' equity of −$119m. It held $89.7m in cash against $0 of debt: net cash of $89.7m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents4114162121552922502711427250430511110590155
Receivables—306524696422929515779107111
Inventory—10——121—207162829856
Total current assets—87534242896467125114164324566517496422404485
Total assets—10982574913712290178147175335588550517490514558
Accounts payable—8244394681419281421121611
Deferred revenue (current)—21011—227020110—012
Total current liabilities—28261715576254756992106104106150160196209
Long-term debt—030303030—23233001201362323033150395
Total debt003030306058515259801532982323033150395
Total liabilities——————————————9729666331,012
Shareholders' equity866615−0−176482844938−19−107−295−456−476−119−454
Net debt (negative = net cash)−41−14149952929132−35−120−206−73193210−90240
Shares outstanding—45m46m51m59m72m73m74m98m110m—177m184m188m206m209m213m255m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: BBIO vs BCRXBCRX vs KNSABCRX vs IONSBCRX vs LEGN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Biocryst Pharmaceuticals Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Biocryst Pharmaceuticals Inc.